10.6084/m9.figshare.11919078.v1
Lesley Scott
Lesley
Scott
Galcanezumab: a review in prevention of migraine and treatment of episodic cluster headache
Adis Journals
2020
Galcanezumab
Prevention of migraine
treatment of episodic cluster headache
review
CGRP mononclonal antibody
Adis Drug Evaluation
2020-06-07 20:28:10
Online resource
https://adisjournals.figshare.com/articles/online_resource/Galcanezumab_a_review_in_prevention_of_migraine_and_treatment_of_episodic_cluster_headache/11919078
<p><b>Compliance
with Ethical Standards</b></p>
<p><b>Funding</b> The preparation of this review was not supported by
any external funding.</p>
<b>Conflict
of interest<i> </i></b>Lesley Scott is a salaried employee of Adis International Ltd/Springer
Nature, is responsible for the article content and declares no relevant
conflicts of interest.<div><br></div><div>Additional information about this Adis Drug Review can be found here<br></div><div><br></div><div>Abstract</div><div><p></p><p>Galcanezumab (Emgality<sup>®</sup>) is a
humanized monoclonal antibody targeting the calcitonin gene-related peptide
(CGRP), thereby inhibiting its physiological activity, with CGRP playing a key
role in the pathophysiology of migraine and headache disorders. In pivotal phase 3 trials,
recommended dosages of subcutaneous galcanezumab once monthly were significantly
more effective than placebo as preventive therapy in adults with episodic (EVOLVE-1
and -2; over 6 months) or chronic (REGAIN; over 3 months) migraine (± aura),
including in patients who had failed several prior preventive migraine drugs
(CONQUER; over 3 months). The beneficial effects of galcanezumab preventive
treatment in reducing the number of monthly migraine headache days (MHDs) and improving
health-related quality of life (HR-QOL) were sustained during up to 1 year of
treatment. In adults with episodic cluster headache, galcanezumab treatment was
associated with a significant reduction in the weekly frequency of cluster
headache attacks across weeks 1–3 compared with placebo (primary endpoint),
albeit during weeks 4 to 8, there was a convergence of results between these treatment
groups. Although further evidence from the clinical setting is required to
determine its long-term safety profile, given its convenient administration
regimen, efficacy and short-term tolerability profile, monthly galcanezumab
represents an important emerging option for the prevention of episodic and
chronic migraine (± aura) and the treatment of episodic cluster headache. </p><p><br></p><p>© Springer
Nature Switzerland AG 2020</p><br></div>